AGEN
Agenus IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$129.51M
P/E Ratio
1.52
EPS
$2.05
Beta
1.60
52W High
$7.34
52W Low
$2.71
50-Day MA
$3.77
200-Day MA
$3.84
Dividend Yield
—
Profit Margin
52.20%
Forward P/E
1.38
PEG Ratio
1.44
About Agenus Inc
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in Lexington, Massachusetts.
Fundamentals
| Revenue (TTM) | $123.87M |
| Gross Profit (TTM) | $120.03M |
| EBITDA | $15.19M |
| Operating Margin | 44.60% |
| Return on Equity | -1279.00% |
| Return on Assets | 2.53% |
| Revenue/Share (TTM) | $3.74 |
| Book Value | $-5.74 |
| Price-to-Book | 218.61 |
| Price-to-Sales (TTM) | 1.05 |
| EV/Revenue | 1.095 |
| EV/EBITDA | 1.07 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 40.20% |
| Shares Outstanding | $41.64M |
| Float | $38.63M |
| % Insiders | 6.68% |
| % Institutions | 23.23% |
Historical Volatility
HV 10-Day
107.86%
HV 20-Day
88.29%
HV 30-Day
96.14%
HV 60-Day
99.38%
HV Rank
55.2%
Volatility is currently expanding
Analyst Ratings
Consensus ($15.50 target)
2
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026